Zura Bio (NASDAQ:ZURA – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.
A number of other brokerages have also recently issued reports on ZURA. Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday, July 1st. William Blair began coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.75.
View Our Latest Stock Analysis on Zura Bio
Zura Bio Stock Performance
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, equities research analysts forecast that Zura Bio will post -0.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Zura Bio
Several institutional investors and hedge funds have recently modified their holdings of the stock. Allworth Financial LP acquired a new stake in shares of Zura Bio during the 4th quarter worth about $30,000. Scientech Research LLC acquired a new position in Zura Bio in the 3rd quarter valued at about $45,000. AQR Capital Management LLC acquired a new position in Zura Bio in the 1st quarter valued at about $72,000. Bank of America Corp DE raised its holdings in Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Zura Bio in the 3rd quarter valued at about $109,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.
About Zura Bio
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
Further Reading
- Five stocks we like better than Zura Bio
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
